Shyam M Srinivas1, Elie C Nasr1, Vamsi K Kunam2, Jennifer A Bullen3, Andrei S Purysko4. 1. Department of Nuclear Medicine, Cleveland Clinic, Cleveland, OH, USA ; 2. Department of Radiology, SUNY Downstate University Hospital, Brooklyn, NY, USA ; 3. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA ; 4. Department of Nuclear Medicine, Cleveland Clinic, Cleveland, OH, USA; ; Section of Abdominal Imaging, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Given the differences in size, specific activity, and dosing methods for glass yttrium-90 microspheres ((90)Y-glass) and resin (90)Y microspheres ((90)Y-resin), these therapies may expose the liver to different amounts of radiation, thereby affecting their efficacy and tolerability. We aimed to compare the prescribed activity of (90)Y-glass and (90)Y-resin for real-world patients undergoing selective internal radiation therapy (SIRT) for liver-dominant metastatic colorectal cancer (mCRC) and to assess efficacy and safety outcomes in these patients. METHODS: We examined the records of 28 consecutive patients with unresectable colorectal liver metastases treated with SIRT between June 2008 and May 2011 at our institution. Using baseline CT and MR images, we calculated a projected activity as if we had used the other product and compared it to the actual prescribed activity of (90)Y-glass and (90)Y-resin for each SIRT treatment per manufacturer guidelines. Progression and adverse events were evaluated at follow up visits. Survival was analyzed by the Kaplan-Meier method. RESULTS: For (90)Y-glass treatments with a mean prescribed (90)Y activity of 1.77 GBq, the mean projected (90)Y-resin activity was 0.84 GBq. For (90)Y-resin treatments with a mean prescribed (90)Y activity of 1.05 GBq, the mean projected (90)Y-glass activity was 2.48 GBq. The median survival was 9.3 months versus 18.2 months for (90)Y-glass and (90)Y-resin, respectively (P=0.292). During the second year after SIRT, the hazard ratio of death for patients treated with (90)Y-glass versus (90)Y-resin was 4.0 (95% CI: 1.3, 12.3; P=0.017). No significant difference in progression, adverse events or liver toxicity was observed. CONCLUSIONS: Using manufacturer recommended guidelines, (90)Y-resin delivers significantly less activity than (90)Y-glass to patients with liver-dominant mCRC undergoing SIRT with no significant difference in adverse events and a trend toward improved survival.
BACKGROUND: Given the differences in size, specific activity, and dosing methods for glass yttrium-90 microspheres ((90)Y-glass) and resin (90)Y microspheres ((90)Y-resin), these therapies may expose the liver to different amounts of radiation, thereby affecting their efficacy and tolerability. We aimed to compare the prescribed activity of (90)Y-glass and (90)Y-resin for real-world patients undergoing selective internal radiation therapy (SIRT) for liver-dominant metastatic colorectal cancer (mCRC) and to assess efficacy and safety outcomes in these patients. METHODS: We examined the records of 28 consecutive patients with unresectable colorectal liver metastases treated with SIRT between June 2008 and May 2011 at our institution. Using baseline CT and MR images, we calculated a projected activity as if we had used the other product and compared it to the actual prescribed activity of (90)Y-glass and (90)Y-resin for each SIRT treatment per manufacturer guidelines. Progression and adverse events were evaluated at follow up visits. Survival was analyzed by the Kaplan-Meier method. RESULTS: For (90)Y-glass treatments with a mean prescribed (90)Y activity of 1.77 GBq, the mean projected (90)Y-resin activity was 0.84 GBq. For (90)Y-resin treatments with a mean prescribed (90)Y activity of 1.05 GBq, the mean projected (90)Y-glass activity was 2.48 GBq. The median survival was 9.3 months versus 18.2 months for (90)Y-glass and (90)Y-resin, respectively (P=0.292). During the second year after SIRT, the hazard ratio of death for patients treated with (90)Y-glass versus (90)Y-resin was 4.0 (95% CI: 1.3, 12.3; P=0.017). No significant difference in progression, adverse events or liver toxicity was observed. CONCLUSIONS: Using manufacturer recommended guidelines, (90)Y-resin delivers significantly less activity than (90)Y-glass to patients with liver-dominant mCRC undergoing SIRT with no significant difference in adverse events and a trend toward improved survival.
Authors: William B Lea; Katie N Tapp; Mark Tann; Gary D Hutchins; James W Fletcher; Matthew S Johnson Journal: J Vasc Interv Radiol Date: 2014-08-23 Impact factor: 3.464
Authors: Andrew S Kennedy; David Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Steven C Rose; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang Journal: J Gastrointest Oncol Date: 2015-04
Authors: Andrea M Abbott; Richard Kim; Sarah E Hoffe; Bulent Arslan; Ben Biebel; Junsung Choi; Ghassan El-Haddad; Bela Kis; Jennifer Sweeney; Kenneth L Meredith; Khaldoun Almhanna; Jonathan Strosberg; David Shibata; William J Fulp; Ravi Shridhar Journal: Clin Colorectal Cancer Date: 2015-02-16 Impact factor: 4.481
Authors: M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen Journal: Eur Radiol Date: 2008-11-07 Impact factor: 5.315
Authors: Andrew S Kennedy; Patrick McNeillie; William A Dezarn; Charles Nutting; Bruno Sangro; Dan Wertman; Michael Garafalo; David Liu; Douglas Coldwell; Michael Savin; Tobias Jakobs; Steven Rose; Richard Warner; Dennis Carter; Stephen Sapareto; Subir Nag; Seza Gulec; Allison Calkins; Vanessa L Gates; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-20 Impact factor: 7.038
Authors: Shyam M Srinivas; Navin Natarajan; Joshua Kuroiwa; Sean Gallagher; Elie Nasr; Shetal N Shah; Frank P DiFilippo; Nancy Obuchowski; Bana Bazerbashi; Naichang Yu; Gordon McLennan Journal: Front Oncol Date: 2014-10-13 Impact factor: 6.244
Authors: Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia Journal: Front Oncol Date: 2014-08-19 Impact factor: 6.244